Avidity Biosciences jumped 43% in premarket after Novartis revealed plans to buy the company for $72 per share in a $12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback